Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cerecor's Depressive Disorder Drug Gains Fast Track | Contract Pharma

What are you searching for?

Sign in

Cerecor’s Depressive Disorder Drug Gains Fast Track

Offers potential to be first rapidly acting antidepressant

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cerecor was granted Fast Track designation by the FDA for its lead clinical product candidate, CERC-301, for major depressive disorder (MDD). CERC-301 is a once daily, oral, adjunctive, selective NMDA receptor subunit 2B (NR2B) antagonist with the potential to be the first in a new class of rapidly acting antidepressants.

The FDA’s Fast Track Drug Development Program is designed to facilitate the clinical development and expedite the review of drugs intended to treat a serious or life-threatening condition, which demonstrate the potential to address an unmet medical need.

Cerecor recently initiated a Phase II clinical study of CERC-301 as an adjunctive treatment for subjects with MDD who have not adequately responded to their current therapy and report recent suicidal ideation.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics